Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | PTGES | O14684 | 5/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TACR2 | P21452 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709742 | 0.97 | BCHE (0.35) | BCHEACHEPTGESATMLMNA | |
| SCHEMBL1709633 | 0.84 | BCHE (0.36) | BCHEACHEPTGESATMLMNA | |
| SCHEMBL10122136 | 0.79 | GHSR (0.39) | BCHEACHEPTGESATMLMNA | |
| SCHEMBL1709572 | 0.78 | GHSR (0.46) | BCHEACHEATMLMNAGAA | |
| SCHEMBL10121858 | 0.77 | GHSR (0.46) | BCHEACHEPTGESLMNAGAA | |
| SCHEMBL1709641 | 0.73 | BCHE (0.36) | BCHEACHEATM | |
| SCHEMBL1709739 | 0.72 | GHSR (0.45) | BCHEACHELMNASMN1; SMN2GAA | |
| SCHEMBL10121974 | 0.71 | GHSR (0.46) | BCHEACHEATMLMNAGAA | |
| SCHEMBL10122141 | 0.71 | GHSR (0.45) | BCHEACHELMNAGAA | |
| SCHEMBL10122251 | 0.69 | GHSR (0.34) | BCHEACHELMNAMAOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | BCHE 1675/4885ACHE 3696/4885PTGES 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.